natgillin/translations-raw huggingface dataset:
Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice.
Alogliptin ni bil karcinogen pri 2-letnih študijah karcinogenosti, izvedenih pri podganah in miših.
Change at Week 52 (n=303)
Sprememba v 52. tednu (n=303)
If this happens, do not drive or use any tools or machines.
V tem primeru ne smete voziti vozil ali upravljati z orodji ali s stroji.
Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea.
Približno ena tretjina bolnikov se je zdravila z insulinom v kombinaciji z metforminom in/ali s sulfonilsečnino.
The study population had an average age of 62 years; the average duration of diabetes was 9.5 years.
Povprečna starost študijske populacije je bila 62 let, povprečno trajanje sladkorne bolezni pa 9,5 let.
ATC code: A10BD09.
Oznaka ATC: A10BD09
Three of the six identified pioglitazone metabolites are active (M-II, M-III, and M-IV).
Aktivni so trije od šestih ugotovljenih presnovkov pioglitazona (M-II, M-III in M-IV).
Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender and body mass index, while differences between races (e.g. White and non-White) were small.
Zmanjšanja vrednosti HbA1c so bila pri različnih podskupinah podobna, tudi pri delitvi glede na okvaro ledvic, starost, spol in indeks telesne mase, razlike med rasami (npr. belci in nebelci) pa so bile majhne.
- if you have diabetic ketoacidosis (a serious complication of poorly controlled diabetes).
• če imate diabetično ketoacidozo (resen zaplet slabo urejene sladkorne bolezni).
Patients should be advised to adhere strictly to a calorie-controlled diet.
Bolnikom je treba svetovati, naj se strogo držijo diete z nadzorovanim vnosom kalorij.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
Higher baseline HbA1c was associated with a greater reduction in HbA1c.
Višja izhodiščna vrednost HbA1c je bila povezana z večjim zmanjšanjem vrednosti HbA1c.
These findings were observed across species at plasma concentrations ≤ 4 times the clinical exposure.
Te izsledke so ugotovili pri vseh živalskih vrstah pri plazemskih koncentracijah, ki so bile ≤ 4-krat večje od klinične izpostavljenosti.
In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces.
Pri živalih je mogoče v blatu ali urinu zaznati le majhno količino nespremenjenega pioglitazona.
Other medicines and Incresync
Druga zdravila in zdravilo Incresync
This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.
Študija je pokazala porast poročil o srčnem popuščanju, vendar pa to v tej študiji ni povzročilo večje umrljivosti.
Common (may affect up to 1 in 10 people): - Sudden and severe bone pain or immobility (particularly in women).
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): • Nenadna in huda bolečina v kosti ali nezmožnost premikanja (predvsem pri ženskah).
Manufacturer Takeda Ireland Limited Bray Business Park Kilruddery
Izdelovalec Takeda Ireland Limited Bray Business Park Kilruddery
• Caution in use in the elderly in light of age related risks (in particular bladder cancer, fractures and heart failure).
• previdnost pri uporabi pri starostnikih v luči tveganj, povezanih s starostjo (še posebej raka sečnega mehurja, zlomov in srčnega popuščanja).
Incresync has no or negligible influence on the ability to drive and use machines.
Zdravilo Incresync nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Both of these groups of medicines are “oral anti-diabetics”.
Obe skupini zdravil spadata med “peroralne antidiabetike”.
What you need to know before you take Incresync
Kaj morate vedeti, preden boste vzeli zdravilo Incresync
The European Medicines Agency has waived the obligation to submit the results of studies with Incresync in all subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Incresync za vse podskupine pediatrične populacije pri zdravljenju sladkorne bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The study demonstrated that alogliptin did not increase the risk of having a MACE compared to placebo [Hazard Ratio: 0.96; 1-sided 99% Confidence Interval: 0-1.16].
Študija je pokazala, da alogliptin ni povečal tveganja za MACE v primerjavi s placebom [razmerje ogroženosti: 0,96; 1-stranski 99 % interval zaupanja: 0-1,16].
The effect of Incresync on fertility in humans has not been studied.
Učinek zdravila Incresync na plodnost pri ljudeh ni bil raziskan.
The mean serum elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.
Povprečni razpolovni čas izločanja nespremenjenega pioglitazona iz seruma pri človeku znaša 5 do 6 ur, za vse njegove aktivne presnovke pa 16 do 23 ur.
When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy.
Ob upoštevanju aktivnosti, koncentracij in vezave na proteine pioglitazon in presnovek M-III enakovredno prispevata k učinkovitosti.
Inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing.
Inhibicija DPP-4 je 24 ur po 14-dnevnem odmerjanju ostala nad 81 %.
STOP taking Incresync and contact a doctor immediately if you notice any of the following serious side effects:
PRENEHAJTE jemati zdravilo Incresync in nemudoma poiščite zdravniško pomoč, če opazite katerega koli od naslednjih resnih neželenih učinkov:
It helps your body make better use of the insulin it produces.
Telesu pomaga bolje izkoristiti insulin, ki nastaja v telesu.
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Incresync.
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila Incresync posvetujte s svojim zdravnikom.
The efficacy and safety of Incresync as triple therapy with a sulphonylurea has not been established and thus use is not recommended.
Učinkovitosti in varnosti zdravila Incresync pri trotirnem zdravljenju s sulfonilsečnino niso dokazali, zato takšna uporaba ni priporočljiva.
(-infinity, -0.28)
(-neskončnost; -0,28)
The inter-subject coefficient of variation for alogliptin AUC was small (17%).
Koeficient variacije vrednosti AUC alogliptina med posameznimi osebami je bil majhen (17 %).
These effects were independent of pioglitazone's effects on glycaemia and were statistically significantly different to glibenclamide.
Ti učinki so bili neodvisni od učinkov pioglitazona na glikemijo in so se statistično pomembno razlikovali od glibenklamida.
This check may be repeated at intervals.
Takšne preiskave bo morda treba opravljati v rednih časovnih presledkih.
It is recommended that you carry some sugar lumps, sweets,
Priporočamo, da imate pri sebi nekaj kock sladkorja, sladkarij, piškotov ali sladek sadni sok.
Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical studies.
O edemih so poročali pri 6-9 % bolnikov, ki so v nadzorovanih kliničnih študijah prejemali pioglitazon več kot eno leto.
Total exposure (AUC(0-inf)) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC(0-24)) after 6 days of once daily dosing.
Skupna izpostavljenost (AUC(0-inf)) alogliptinu po prejemu enkratnega odmerka je bila podobna izpostavljenosti med obdobjem prejemanja enega odmerka (AUC(0-24)) po 6 dnevih odmerjanja enkrat na dan.
Generally, the effects of alogliptin on body weight and lipids were neutral.
Na splošno so bili učinki alogliptina na telesno maso in lipide nevtralni.
Before you start taking this medicine you will have a blood sample taken to check your liver and kidney function.
Pred uvedbo zdravljenja s tem zdravilom boste oddali vzorec krvi, na katerem bodo preverili delovanje jeter in ledvic.
However, patients who experience visual disturbance should be cautious when driving or using machines.
Vendar pa morajo biti bolniki z motnjami vida pri vožnji vozil ali upravljanju s stroji previdni.
What Incresync is and what it is used for
Kaj je zdravilo Incresync in za kaj ga uporabljamo
Liver enzymes should be checked prior to the initiation of therapy in all patients.
Jetrne encime je treba pred začetkom zdravljenja preveriti pri vseh bolnikih.
If you are following a diabetic diet, you should continue with this while you are taking Incresync.
Če ste na diabetični dieti, morate z njo med jemanjem zdravila Incresync nadaljevati.
Incresync should be taken once daily with or without food.
Zdravilo Incresync je treba jemati enkrat na dan s hrano ali brez nje.
It is not known if alogliptin is removed by peritoneal dialysis.
Ni znano, če se alogliptin lahko odstrani s peritonealno dializo.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Incresync therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Incresync, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
(Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing.
(Bolniki s končno ledvično odpovedjo so prejeli hemodializo neposredno po prejemu odmerka alogliptina.
• The risk of heart failure and relevant risk minimisation advice.
• tveganje za srčno popuščanje in ustrezen nasvet za zmanjšanje tveganja.
No data are available (see section 4.2).
Podatkov ni na voljo (glejte poglavje 4.2).
After initiation of therapy with Incresync, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c).
Tri do 6 mesecev po uvedbi zdravljenja z zdravilom Incresync je treba bolnike ponovno pregledati in oceniti ustreznost odziva na zdravljenje (npr. znižanje vrednosti HbA1c).
10 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 56 film-coated tablets 60 film-coated tablets 90 film-coated tablets 98 film-coated tablets 100 film-coated tablets
10 filmsko obloženih tablet 14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 56 filmsko obloženih tablet 60 filmsko obloženih tablet 90 filmsko obloženih tablet 98 filmsko obloženih tablet 100 filmsko obloženih tablet
- if you are elderly and are taking insulin, because you may have an increased risk of heart problems.
• če ste starostnik in se zdravite z insulinom, saj je v tem primeru tveganje za pojav težav s srcem lahko večje.
In some cases, weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored.
V nekaterih primerih je povečanje telesne mase lahko simptom srčnega popuščanja, zato je treba telesno maso skrbno nadzirati.
Part of the treatment of diabetes is dietary control.
Del zdravljenja sladkorne bolezni je tudi kontrola telesne mase z dieto.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Ta večinoma poteka preko citokroma P450 2C8, čeprav so lahko v manjši meri udeležene tudi druge izooblike.
Total serum concentration of pioglitazone is unchanged, but with an increased volume of distribution.
Skupna koncentracija pioglitazona v serumu se ne spremeni, volumen porazdelitve pa je večji.
Patients should be alerted to the risk of hypoglycaemia when Incresync is used in combination with other anti-diabetic medicinal products known to cause hypoglycaemia.
Bolnike je treba opozoriti na možnost pojava hipoglikemije, če se zdravilo Incresync uporablja v kombinaciji z drugimi antidiabetiki, za katera je znano, da povzročajo hipoglikemijo.
You can take this medicine with or without food.
To zdravilo lahko jemljete s hrano ali brez nje.
Taking Incresync in combination with other anti-diabetic medicines can cause low blood sugar levels (hypoglycaemia), which may affect your ability to drive and use machines.
Pri jemanju zdravila Incresync v kombinaciji z drugimi antidiabetiki se lahko vrednost krvnega sladkorja prekomerno zniža (hipoglikemija), kar lahko vpliva na sposobnost za vožnjo vozil in upravljanje s stroji.
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away.
Če ste vzeli večji odmerek zdravila Incresync, kot bi smeli Če ste vzeli več tablet, kot bi smeli, ali pa je vaše zdravilo vzela druga oseba ali otrok, se nemudoma obrnite na najbližji center za nujno medicinsko pomoč ali se odpravite tja.
Effects of other medicinal products on alogliptin
Učinki drugih zdravil na alogliptin
This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level.
To izobraževalno gradivo je namenjeno ozaveščanju o pomembnih ugotovljenih tveganjih za rak sečnega mehurja in srčno popuščanje ter o splošnih priporočilih, da bi dosegli najboljše razmerje med koristjo in tveganjem na ravni bolnika.
Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals.
Kaže, da pioglitazon deluje preko aktivacije specifičnih jedrnih receptorjev (receptor gama, ki ga aktivira peroksisomski proliferator), kar pri živalih privede do povečane občutljivosti jetrnih, maščobnih in skeletno-mišičnih celic za insulin.
Pack sizes of 10, 14, 28, 30, 56, 60, 90, 98 or 100 film-coated tablets.
Velikosti pakiranj: 10, 14, 28, 30, 56, 60, 90, 98 ali 100 filmsko obloženih tablet.
Incresync is available in blister packs containing 10, 14, 28, 30, 56, 60, 90, 98 or 100 tablets.
Zdravilo Incresync je na voljo v pretisnih omotih, ki vsebujejo 10, 14, 28, 30, 56, 60, 90, 98 ali 100 tablet.
Specific pharmacokinetic drug interaction studies have not been performed with Incresync.
Specifične študije farmakokinetičnih interakcij z zdravilom Incresync niso bile izvedene.
Risk related to alogliptin
Tveganja, povezana z alogliptinom
Studies in lactating rats indicate that alogliptin is excreted in milk.
Študije pri podganah med laktacijo kažejo, da se alogliptin izloča v mleko.
Investigations weight increased common alanine aminotransferase increased not known
Preiskave povečanje telesne mase pogosti zvišanje vrednosti alanin-aminotransferaze neznana
No environmental impact is anticipated from the clinical use of pioglitazone.
Vpliv na okolje pri klinični uporabi pioglitazona ni pričakovan.
Pioglitazone or placebo was added to existing anti-diabetic and cardiovascular therapy for up to 3.5 years.
Pioglitazon ali placebo so dodali k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, zdravljenje pa je trajalo do 3,5 let.
Immune system disorders hypersensitivity not known hypersensitivity and allergic reactions not known
Bolezni imunskega sistema preobčutljivost neznana preobčutljivostne in alergijske reakcije neznana
Incresync should not be used in patients with type 1 diabetes mellitus.
Zdravila Incresync se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1.
This is similar to that seen in a sulphonylurea active comparator group.
To je podobno kot v primerjalni skupini, ki je prejemala sulfonilsečnino.
If ALT levels are increased to 3 x upper limit of normal during therapy, liver enzyme levels should be reassessed as soon as possible.
Če se med zdravljenjem vrednosti ALT zvišajo na 3-kratno zgornjo mejo normalnih vrednosti, je treba vrednost jetrnih encimov čim prej znova ovrednotiti.
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9.
Alogliptin je močan in zelo selektiven zaviralec DPP-4, ki je več kot 10.000-krat bolj selektiven za DPP-4 kot za druge sorodne encime, vključno z DPP-8 in DPP-9.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%.
Delež edemov v skupinah s primerjalnim zdravilom (sulfonilsečnina, metformin) je bil 2-5 %.
Do not take Incresync: - if you are allergic to alogliptin, pioglitazone or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na alogliptin, pioglitazon ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure.
Pioglitazon lahko povzroči zastajanje tekočine, kar lahko poslabša ali povzroči srčno popuščanje.
- if you have or have ever had bladder cancer.
• če imate ali ste kdaj imeli rak sečnega mehurja.
If you have kidney problems your doctor may prescribe you a reduced dose.
Če imate težave z ledvicami, vam zdravnik lahko predpiše manjši odmerek.
What Incresync is and what it is used for What you need to know before you take Incresync How to take Incresync
Kaj je zdravilo Incresync in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Incresync Kako jemati zdravilo Incresync Možni neželeni učinki
After excluding patients in whom exposure to the medicinal product was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups.
Po izključitvi bolnikov, ki so bili v času diagnoze raka sečnega mehurja zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06 %) raka sečnega mehurja pri pioglitazonu in 2 primera (0,02 %) v kontrolnih skupinah.
Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown.
Medsebojno delovanje s substrati za izooblike CYP 450 tako ni pričakovano in tudi ni bilo ugotovljeno.
The observed excess risk of fractures for women in this dataset on pioglitazone is, therefore, 0.8 fractures per 100 patient years of use.
Opaženo čezmerno tveganje za zlome pri ženskah v tem naboru podatkov za pioglitazon je tako 0,8 zlomov na 100 bolnikov-let uporabe zdravila.
In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type 2 diabetes mellitus already being treated with this combination.
Poleg tega je zdravilo Incresync mogoče uporabiti za nadomestitev ločenih tablet alogliptina in pioglitazona pri tistih odraslih bolnikih, starih 18 let in starejših, s sladkorno boleznijo tipa 2, ki se že zdravijo s to kombinacijo.
In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development.
V študiji prenatalnega in postnatalnega razvoja pri podganah izpostavljenosti, ki so daleč presegale izpostavljenost človeka pri priporočenem odmerku, niso škodile razvijajočemu se zarodku ali vplivale na rast in razvoj mladičev.
If you are already taking both alogliptin and pioglitazone as single tablets, Incresync can replace them in one tablet.
Če že jemljete alogliptin in pioglitazon v obliki ločenih tablet, jih zdravilo Incresync lahko nadomesti z eno samo tableto.
If you stop taking Incresync
Če ste prenehali jemati zdravilo Incresync
See section 2 “Incresync contains lactose”.
Glejte poglavje 2 “Zdravilo Incresync vsebuje laktozo”.
Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back.
Bolnike je treba seznaniti z značilnim simptomom akutnega pankreatitisa, to je trdovratno in hudo bolečino v trebuhu, ki lahko izžareva v hrbet.
Slight changes in cell counts may show up in blood tests.
Krvne preiskave lahko pokažejo rahle spremembe števila krvnih celic.
• The risk of bladder cancer and relevant risk minimisation advice.
• tveganje za nastanek raka sečnega mehurja in ustrezen nasvet za zmanjšanje tveganja.
- if you have a problem with your liver or kidneys.
• če imate težave z jetri ali ledvicami.
The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.
Edemi so bili v splošnem blagi do zmerni in zaradi njih zdravljenja običajno ni bilo treba prekiniti.
If ALT levels remain > 3 x the upper limit of normal, therapy should be discontinued.
Če vrednosti ALT ostanejo večje od 3-kratne zgornje meje normalnih vrednosti, je treba zdravljenje prekiniti.
The efficacy and safety of the recommended doses of alogliptin and pioglitazone in a subgroup of patients with type 2 diabetes mellitus and ≥ 65 years old were reviewed and found to be consistent with the profile obtained in patients < 65 years old.
Učinkovitost in varnost priporočenih odmerkov alogliptina in pioglitazona v podskupini bolnikov s sladkorno boleznijo tipa 2, starih 65 let ali starejših, sta bili ponovno pregledani in ugotovljeno je bilo, da sta konsistentni s profilom, pridobljenim pri bolnikih, mlajših od 65 let.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/842/001-036
EU/1/13/842/001-036
Concomitant treatment with alogliptin and pioglitazone did not produce new toxicities, nor did it exacerbate any pioglitazone-related findings.
Sočasno zdravljenje z alogliptinom in s pioglitazonom ni povzročilo novih toksičnih učinkov in ni poslabšalo nobene ugotovitve, povezane s pioglitazonom.
The MAH shall provide an educational pack targeting all physicians who are expected to prescribe/use alogliptin/pioglitazone.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti izobraževalno gradivo, namenjeno vsem zdravnikom, za katere se pričakuje, da bodo predpisovali/uporabljali alogliptin/pioglitazon.
Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers and HMGCoA reductase inhibitors, are not to be expected.
Medsebojnih delovanj z zdravili, ki se presnavljajo s temi encimi, npr. s peroralnimi kontraceptivi, ciklosporinom, z zaviralci kalcijevih kanalčkov in zaviralci reduktaze HMGCoA, ni pričakovati.
In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily.
V kliničnih študijah so bolniki prejemali pioglitazon v odmerkih, večjih od največjega priporočenega odmerka 45 mg na dan.
No increase in mortality from heart failure was observed.
Večje umrljivosti zaradi srčnega popuščanja niso opazili.
Patients (≥ 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients < 65 years old.
Bolniki (stari 65 let ali starejši) s sladkorno boleznijo tipa 2 veljajo za bolj dovzetne za epizode hipoglikemije kot bolniki, mlajši od 65 let.
Therapy with Incresync should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 x upper limit of normal) or with any other evidence of liver disease.
Zdravljenja s pioglitazonom se ne sme uvesti pri bolnikih z izhodiščno zvišano vrednostjo jetrnih encimov (ALT > 2,5-kratna zgornja meja normalnih vrednosti) ali s katerim koli drugimi znakom bolezni jeter.
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone.
Čeprav študija ni dosegla primarnega opazovanega dogodka, ki je bil sestavljen iz umrljivosti zaradi vseh vzrokov, neusodnega miokardnega infarkta, možganske kapi, akutnega koronarnega sindroma, velike amputacije na nogah, koronarne revaskularizacije in revaskularizacije na nogah, rezultati kažejo, da glede uporabe pioglitazona ni dolgoročnih kardiovaskularnih zadržkov.